SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff in AI neocloud stocks, fueled by concerns about debt, financing costs and the sustainability of data-center spending, is weighing on Nebius alongside CoreWeave-related credit fears. Traders are split between calling NBIS oversold and expecting a rebound, and warning that sector pressures could drive further declines; some argue Nebius has a stronger balance sheet than peers.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

S&P 500 futures surged after a tech-led selloff, prompting traders to debate whether the rebound ahead of major tech earnings is a genuine recovery or a short-covering bounce that could fade. The move also undercut Black Monday anniversary fears, though many remain wary that the futures rally may not hold at the market open.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO data are driving attention, especially mature results for lifileucel plus pembrolizumab in frontline melanoma, where traders highlight durable responses and progression-free survival as support for the ongoing Phase 3 trial. Reactions are mixed: some view the results as encouraging confirmation, while others say the small cohort and overlap with earlier data limit the news; early sarcoma results are also being discussed as promising but preliminary.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention amid steep selling pressure, with traders focused on scheduled insider share unlocks and a broader AI and semiconductor-sector downturn; concerns about its high valuation, growth and reliance on major customers add to the bearish case. Some investors see the selloff as an oversold buying opportunity, while others expect further declines and debate how much is due to lockup-related supply versus weak sector sentiment.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders watching for the 80th death event that triggers final analysis after the last disclosed count of 78; the prolonged wait and company silence have fueled speculation about unusually long patient survival and possible ASH data, but those interpretations remain unconfirmed. The debate is reflected in bullish expectations for a positive readout and skepticism that the delay or conference booth signals anything, amid concern over the stocks sharp decline.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs new index rules could make Strategy eligible for removal, raising concern about potential forced selling by index-tracking funds and contributing to the sharp share decline. Traders debate whether the risk is already priced in, while also weighing Bitcoins weakness and MSTRs steeper fall against dip-buying optimism.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereums sharp swings alongside a weak broader crypto market have put its ability to hold support and reclaim resistance at the center of discussion. Traders are split between viewing the rebound as a bear trap and expecting further downside, while others see dip buying and short positioning as signs of a recovery.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFRs steep selloff is being tied to its convertible-note financing and dilution concerns, alongside broader worries about AI data-center spending, project costs and financing conditions. Traders are split between viewing the decline as an overreaction and warning that added shares, debt and execution risks could prolong the pressure.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Anticipation around SpaceXs Q3 earnings is driving attention, with traders focused on Starlink and AI-compute growth and whether it can support heavy investment. The conversation is split between hopes for strong results and merger-related upside, and concerns about spending, valuation, and a large insider-share unlock.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech-led selloff followed by a strong futures rebound has traders debating whether dip-buying and short covering signal a recovery or a bull trap. Black Monday anniversary fears added to the volatility, while upcoming mega-cap earnings are seen as a test for tech sentiment.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 Stocks to Buy Using the Relative Price Strength Strategy

HALO, GCT, LIND, PR and CVX stand out as relative strength picks amid market volatility, backed by strong price performance and upbeat earnings estimates.

Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease

RHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.


Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Top Research Reports for Mastercard, AstraZeneca & Sandisk

Mastercard's payment growth, AstraZeneca's drug pipeline and Sandisk's AI-driven SSD demand headline today's top research reports, revealing key growth drivers and risks for investors.

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Here's How Much $100 Invested In Halozyme Therapeutics 5 Years Ago Would Be Worth Today

Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 5 years by 12.8% on an annualized basis producing an average annual return of 24.48%. Currently, Halozyme Therapeutics has a marketread more...

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

HALO Wins Court Order Blocking Merck's Keytruda SC in Europe

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics Inc.

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Equity

Extremely Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

HALO News